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ABSTRACT 
The non-invasive nature of volatile organic compound (VOC) sampling from skin makes 
this a priority in the development of new screening and diagnostic assays. Evaluation of 
recent literature highlights the tension between the analytical utility of ambient ionisation 
approaches for skin profiling and the practicality of undertaking larger campaigns (higher 
statistical power), or undertaking research in remote locations. This study describes how 
VOC may be sampled from skin and recovered from a polydimethylsilicone sampling 
coupon and analysed by thermal desorption (TD) interfaced to secondary electrospray 
ionisation (SESI) time-of-flight mass spectrometry (MS) for the high throughput screening 
of volatile fatty acids (VFAs) from human skin.  
Analysis times were reduced by 79% compared to gas chromatography-mass 
spectrometry methods (GC-MS) and limits of detection in the range 300 to  900 pg cm -2 
for VFA skin concentrations were obtained.  
Using body odour as a surrogate model for clinical testing 10 Filipino participants, 5 high 
and 5 low odour, were sampled in Manilla and the samples returned to the UK and 
screened by TD-SESI-MS  and TD-GC-MS  for malodour precursors with greater than 
>95% agreement between the two analytical techniques. Eight additional VFAs were also 
identified by both techniques with chains 4 to 15 carbons long being observed. TD-SESI-
MS appears to have significant potential for the high throughput targeted screening of 
volatile biomarkers in human skin.   
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INTRODUCTION 
Analysis of the volatile organic compound (VOC) profile of human skin is an alternative, 
non-invasive, approach to invasive blood-based methodologies for diagnosis and 
studying human function. VOCs observed on and in skin are derived from: glandular 
secretions; perfusion from underlying blood vessels; products of micro-biological 
metabolism; and exogenous components (Environmental contamination and personal 
care products for example) [1-2].  The highly individualised and dynamic nature of these 
profiles, and the utility of skin profiling have been reviewed [3]. 
Sampling techniques for skin VOC profiles include: whole sweat collection [4-5]; liquid 
extraction [6-7]; adsorbent materials placed in direct contact with the skin surface [2, 8,-
14] or headspace approaches [6, 9, 15-16].  Analysis of skin has identified many types of 
VOC, and the list includes: volatile fatty acids (VFAs), aldehydes, alcohols, aliphatic and 
aromatic hydrocarbons, amides, amines, esters, halides, ketones and volatile sulphur 
compounds (VSCs) [2-3]. Multi-variate analysis (MVA) indicates gender specific 
information within such profiles [13, 17]. Studies of skin VOC profiles have identified 
mosquito attractants [11-12] and monitored fragrance release [9-10]. Compounds 
associated with chronic wounds [18] as well as signatures differentiating between 
melanoma, naevi and healthy skin [19] have been reported. Skin profiling has also been 
applied to ammonia monitoring; non-invasive headspace capture of ammonia from skin 
enabled such an approach to be compared against blood gas levels. These measures 
were correlated (R=0.84, p<0.01) and the approach was extended to proof-of-concept 
screening for hepatic disease with  median levels of ammonia release from the skin of 
subjects with liver disease estimated to be ca. 3 ng cm-2 (N=24), compared to ca. 2 ng 
cm-2 (N=24) in healthy controls [20].  
The foundations for such skin profiling studies are to be found in research on body 
odour. Individual skin profiles have been developed as ‘barcodes’ of scent for forensic 
[21] and diagnostic application [22],  and gender and age specific signatures have been 
proposed as contributing factors to an individual’s profile [23-26]. Olfactory analysis, 
either in-vivo or by organoleptic analysis of chromatographic eluents [27], combined with 
analytical measurement have established levels of odour to correlate with VSCs and 
VFAs, with 3-methyl-2-hexenoic acid cited as a critical molecular factor [26-28].  Finally, 
the quantity of anecdotal evidence of canine olfaction of disease, increasingly supported 
by scientific studies [29-32], reinforces the proposition of non-invasive skin VOC profiling 
for diagnosis and condition monitoring. 
Direct contact and headspace skin sampling devices generally employ thermal 
desorption (TD) for the recovery of VOCs which is interfaced to gas chromatography (GC), 
mass spectrometry (MS) [3]. Such approaches generate extensive VOC profiles that are 
rich in information, and are potentially useful for global profiling and non-targeted 
biomarker discovery. However, such analytical workflows are time consuming, and an 
analysis time of more than an hour per sample mitigates against the large sample 
numbers needed to validate markers and is too long for high throughput analysis or 
clinical screening applications.  
“Ambient” mass spectrometry approaches, where samples are introduced directly to an 
external ionisation source, for skin analysis provide rapid and sensitive analysis. Mass 
spectral “fingerprints” obtained in-vivo from skin with desorption electrospray ionisation 
(DESI) [33], secondary electrospray ionisation (SESI) [34-35] and extractive electrospray 
ionisation (EESI) [36] are exciting and promising developments. Selected ion flow tube 
mass spectrometry (SIFT-MS) has provided real-time information for acetone emanating 
from skin [37] and proton transfer reaction mass spectrometry (PTR-MS) has been 
applied to monitoring of lipid peroxidation products and the fatty acid composition of skin 
[38]. All these methods enable fast, selective and sensitive analysis of the area of a 
participant’s skin presented to the instrument. These approaches, whilst offering a 
distinct time advantage, require the participant to present a part of their body to the 
instrument, which is not always practical. Further, consider for example, the practicalities 
of sampling and analysing a lot of participants’ skin over a short period. The difficulty 
increases if the study encompasses a large geographic region, or remote locations. 
Clinical safety considerations and risk assessments also require instruments and 
systems to be sterile before use with a patient; repeatedly dousing sensitive instruments 
for VOC analysis with disinfectant is a problematic protocol. 
Recently thermal desorption secondary electrospray ionisation-ion mobility-mass 
spectrometry (TD-SESI-IM-MS) was  proposed for rapid breath screening as an alternative 
to TD-GC-MS. The potential for rapidly generating high-fidelity mass spectra of exhaled 
breath VOC without a lengthy chromatography  step was  demonstrated [39], and the 
current work is informed by this approach, with the aim of  describing the targeted 
analysis of VFAs present in and on human skin.  
Sampling skin with polydimethylsiloxane (PDMS) coupons (0.5 cm2 0.5 mm thick) placed 
on the skin surface with analysis by thermal desorption gas chromatography mass 
spectrometry has been proposed for targeted and non-targetted analysis of VOC skin 
metabolites and catabolites. The relative standard deviation (RSD) of this approach 
varies with analyte volatility, with values between 7 and 19% observed during in-vitro 
tests. In-vivo, RSD values up to a maximum of 32% have been observed; for trace levels 
of a methylated hydrocarbon tentatively assigned to 3,7-dimethyloct-1-ene, and limits of 
detection were estimated to be of the order of 50pg  [1]. The sensitivity, reproducibility, 
comfort and ease-of-use of a PDMS skin-patch sampler makes for a practical and 
straightforward methodology for undertaking more extensive studies on human skin, 
either in clinic or in the field.  
The current research combined the sampling attributes of a ‘skin patch’ with thermal 
desorption secondary electrospray ionisation-mass spectrometry (TD-SESI-MS) [39]. TD-
SESI-MS was found to have limits of detection no higher than 1 ng per sample, with an 
in-vivo RSD of 13.5%. The most relevant analytical characteristic to this study was a 
mass accuracy of 1.4 ppm enabling metabolite identities to be assigned with a high level 
of confidence. The combination of skin patch samples with TD-SESI-MS provides a high-
throughput, clinically compatible and scalable methodology for targeted metabolite/VOC  
analysis  of human skin.   
The aim of this study was to evaluate the potential of skin patch sampling with TD-SESI-
MS analysis for phenotypic screening, potential diagnostic applications and 
characterisation of skin metabolism. To do this a panel of volunteer participants was 
recruited, with half of them having a genetic trait relating to “body odour”. The specific 
hypothesis was that a single nucleotide polymorphism (SNP), 538G→A, caused a G180R 
substitution in the ABCC11 gene that would result in reduced concentrations of apocrine 
derived axillary odour precursors, with special emphasis on 3-methyl-2-hexenoic acid [40-
41].  In other words half of our participants would have the genetic attribute of apocrine 
secretions that did not contain 3-methyl-2-hexenoic acid; they did not have a 
characteristic “sweaty smell”. Five other skin metabolite VFA’s were also included in the 
study (butanoic acid, 2 methylpropanoic acid, pentanoic acid, 3-methylbutanoic acid and 
hexanoic acid). These analytes were not expected to be affected as strongly by the SNP 
and their presence in the screen would indicate that the absence of 3-methyl-2-hexenoic 
acid was not attributable to a measurement artefact and a reduction in the efficiency of 
analyte recovery. The resultant data were to be compared to those derived from a 
thermal desorption gas chromatograph electron ionisation time-of-flight mass 
spectrometer (TD-GC-ToFMS) and an organoleptic assessment of malodour. 
EXPERIMENTAL 
Ethics and Participant Preparation 
This research was conducted in accordance with the ethical principles of Good Clinical 
Practice and the Declaration of Helsinki. The local ethics committee approved the study 
before commencement of the work, and all subjects gave written informed consent. 
Caucasians and Africans possess a strong axillary distinctive smell, whereas many Asians 
don’t. There is evidence that the gene ABCC11 is an important factor in the formation of 
axillary odour. Further recent studies have proposed that a single-nucleotide 
polymorphism (SNP) 538G → A, leads to individuals having no characteristic axillary 
odour. This SNP is prominent among Asian people, hence a consumer test centre in 
Manila was selected as the sampling point. [40, 41]. Healthy female subjects, aged 
between 20 and 55 years of age were recruited for this study, following a qualifying 
medical questionnaire. Participants on medication, suffering from any skin disorder or 
systemic disease or if with a history of being sensitive to underarm personal care 
products were excluded.  
Participants were requested not to use antiperspirant or deodorant products in the 
3 week pre-test period, and instructed to wash their underarm area with nothing but un-
fragranced liquid soap. All samples were taken at the Unilever Consumer Studies Centre 
(Manila, Philippines).   
Sampling 
The PDMS skin sampling patches (Goodfellow Cambridge Limited) were prepared for use  
by cleaning with ultrasonic washing in methanol at 30°C and then individually placed 
inside clean, empty thermal desorption tubes. These were then heated to 185°C under 
vacuum for 15 hours. Final conditioning of the patches involved purging with purified 
helium at 50 cm3 min-1 and 185 ºC for 20 minutes. Each prepared skin patch was 
analysed by (TD-GC-MS) to verify that it was free from contamination. The thermal 
desorption tube containing the skin sampling patch was then removed from the thermal 
desorber and immediately sealed with Swagelok caps and shipped from Loughborough 
University to Manila in the Philippines where the samples were taken.  
Prior to VOC sampling, the intensity of the participants’ axillary odour was evaluated 
organoleptically by six independent assessors against a set of standard solutions of the 
target VFAs and assigned a malodour score from 1 to 5; 1 being the weakest discernable 
odour and 5 the most intense. The mean of the four scores was taken as the mean 
malodour score (MMS) for the participant. In this pilot study 5 participants with high a 
organoleptic assessment of VFA odour (MMS 3 to 5) and 5 participants with low 
organoleptic assessments (MMS 1 – 2.5) were selected. 
A VFA skin sample was obtained from each participants’ axilla with a prepared skin patch 
that was removed from a sealed thermal desorption tube and immediately placed on the 
skin surface and covered with a cotton pad (conditioned previously under vacuum at 
70ºC for 15 hours and then stored in an air tight package until use). The skin sampling 
patch was left in place for 30 min before it was removed and immediately resealed 
inside the thermal desorption tube [1], which was then rapidly cooled to -80 ºC and 
returned to the laboratory for analysis.  
Instrumentation 
Thermal Desorption Secondary Electrospray Ionisation Time-of-Flight Mass Spectrometry 
(TD-SESI-MS ) 
The modification of an electrospray source to TD-SESI-MS has been described elsewhere 
[40]. Briefly, the outlet transfer line (0.25mm i.d deactivated fused silica) from a thermal 
desorption unit (Markes International UNITY 1) was interfaced to the electrospray source 
of an ion mobility-quadrupole time-of-flight mass spectrometer (Waters Synapt) operating 
with the ion mobility off.The front of the ionisation source was removed along with the 
lockspray baffle plate and the reference sprayer assembly to accommodate the heated 
shroud of the transfer line and allow accurate positioning of the end of the capillary. The 
capillary end was aligned 0.5 to 1 cm from the sample cone of the mass spectrometer 
and 5mm from the electrospray emitter. This ensured that the desolvation gas focused 
the gaseous sample stream from the capillary tip towards the sample cone.  
It is important to note that this procedure required electrical isolation switches within the 
ionisation assembly to be defeated. Physical barriers, warning signs and exclusion areas 
were used to reduce the risk from this electrical hazard. 
Analysis of the skin sampling patches entailed 10 min thermal desorption at 180°C with 
a Helium flow of 6 cm3 min-1. The desorbed products were concentrated in a cold trap 
held at  -10°C and packed with a dual sorbent bed of Tenax and Carbograph-1TD 
(Markes International, U-T2GPH), injection to the SESI source involved ballistic heating of 
the “cold-trap” at 32°C s-1 to 300 °C. The “cold-trap” was maintained at 300°C for 5 
min. The transfer line was maintained at 150°C.  An important aspect of the quality 
assurance of this process was the inclusion of blank runs before and after each sample 
to verify that the instrument was free of contamination and that no residual analyte 
remained in the sample coupon or within the analytical pathway. 
The mass spectrometer was operated in negative mode with: a capillary voltage of 3 kV, 
a cone voltage of 10 V, a source temperature of 120°C, and a desolvation temperature 
of 150°C. The desolvation gas was nitrogen supplied at a flow 5 dm3 min-1. No cone gas 
was supplied in this study. The electrospray solvent was unbuffered 50/50 (v/v) 
methanol/water infused into the source at 5 μl min-1.  
Thermal Desorption Gas Chromatography Time-of-Flight Mass Spectrometry (TD-GCToF-
MS) 
Sample recovery was by thermal desorption (Markes International, UNITY 2) of the skin 
sampling patches interfaced to a GC-ToF-MS (Waters GCT Premier gas chromatograph 
time-of-flight mass spectrometer). Skin patches were thermally desorbed at 180°C for 
10 min with a 50 cm3 min-1 helium flow to a cold trap held at -10°C. Injection from the 
cold trap was achieved by ballistic heating at 32°C s-1 to 300 °C. This temperature was 
maintained for 5 min with a 1/10 split, the transfer line temperature was 150 °C. The 
gas chromatograph was fitted with a 0.25mm i.d., 60m long capillary column with a 
stationary phase thickness of 2.5 µm. The stationary phase was a 5% phenyl, 95% 
methyl polysiloxane stationary phase (Cat no: 122-5562 Agilent DB-5MS), the 
temperature programme had an initial temperature of 40 °C, 0 min hold, that increased 
at 5°C min-1 to 310°C where it was held for 6 minutes. The GC was operated at constant 
head pressure of 172 kPa (25 psi). The electron impact source was operated in the 
positive mode at a temperature of 200°C, with an electron energy of 70eV. The mass 
spectrometer cycle time was 0.1 s (scan duration 0.09s, interscan delay 0.01 s) with a 
mass-range of 40 to 550. 
Preparation of standards 
Standard mixtures for evaluation of mean malodour score and instrument calibration of 
the target VFA metabolites were prepared. The stock solution contained butanoic acid ( 
4.8 μg cm-3), 2-methylpropanoic acid  acid (4.8 μg cm-3 ), pentanoic acid (17 μg cm-3 ),3-
methylbutanoic acid (17 μg cm-3 ), hexanoic acid (10 μg cm-3 ) and 3-methyl-2-hexenoic 
acid (100 μg cm-3) all dissolved in high purity methanol. This stock solution was 
designated to have an organoleptic mean malodour score (MMS) of 5; a strong sensation 
of malodour for most humans. Lesser strength solutions to mimic MMS 4 and below 
were then prepared by sequential 4-fold dilutions.  
5 μl aliquots, the approximate volume of a droplet of an apocrine secretion [1], of the 
MMS 3 mixture were directly deposited onto blank skin patches in thermal desorption 
tubes during the thermal desorption and electrospray optimisation studies. Each of these 
aliquots contained 1.5 ng of butanoic and 2-methylpropanoic acid, 5 ng of pentanoic and 
3-methylbutanoic acid, 3 ng of hexanoic acid and 30 ng 3-methyl-2-hexenoic acid.  
RESULTS AND DISCUSSION 
Approximately 600 mass spectrometric peaks were isolated from each sample in the 
negative mode over a 4 min profile, see the bottom trace in Figure 1 obtained from a 
participant without the (SNP) 538G→A who had a high organoleptic mean malodour 
score (MMS) of 4. Individual compounds were resolved on the basis of selected ion mass 
spectrometry. Butanoic and 2-methylpropanoic acid yield isobaric ions, as do pentanoic 
and 3-methylbutanoic acid and these pairs of isomers were combined. This gave four VFA 
targets that were designated as, C4 VFA (butanoic and 2-methylpropanoic), C5 VFA 
(pentanoic and 3-methylbutanoic), H (hexanoic) and 3M2H (3-methyl-2-hexenoic) acids. 
Some separation between the VFA targets was observed in the thermal desorption 
profiles with C4 VFA (boiling point (BP) 164°C/155°C) eluting earliest followed by C5 
VFA (BP 186°C/175°C), hexanoic acid (BP 203°C) and 3-methyl-2-hexenoic acid (BP 
225°C) eluting last, Figure 1. This partial separation introduced an element of selectivity 
into the sample introduction, and as such was thought to mitigate somewhat the effects 
of competitive ionisation from higher molecular weight skin matrix components.  
Note that including the ion mobility function of the mass spectrometer was not helpful in 
this study for the resultant reduction in mass accuracy outweighed any selectivity 
benefits derived from a low-resolution T-wave ion mobility separation. 
Limits of detection, determined from on-patch mass and signal-to-noise ratios were 
estimated to be no higher than: 500 pg for butanoic/2-methylpropanoic acid (C4 VFA); 
900 pg for pentanoic/3-methylbutanoic acid (C5 VFA); 300 pg hexanoic acid (H); and 
350 pg 3-methyl-2-hexenoic acid (3M2H). These levels were below the 1.9 ng odour 
threshold previously reported for 3-methyl-2-hexenoic acid [28].  
Skin Sample Analysis 
The thermal desorption tubes containing the skin sampling patches were removed from -
80°C storage and warmed for 5 min at room temperature before loading into the 
thermal desorber for analysis. Figure 1 shows desorption profiles obtained from a skin 
sample provided by participant with an MMS = 4, contrasted against a blank skin patch. 
The skin sample provided a complicated desorption profile with VOC components eluting 
for up to four minutes after the start of the ballistic heating of the cold trap. Figure 1 also 
shows the magnified (x 100) mass selected desorption profiles of the four target VFAs 
(C4 VFA, C5 VFA, H, and 3M2H). The partial separation, based on volatility, of the target 
VFAs is also evident. 
<< Figure 1 near here.>> 
Figure 2 contrasts the mass spectrum from the skin sample in Figure 1 against the mass 
spectrum of the blank skin patch and a number of background ions as well signals from 
the blank skin patch and the skin sample are evident. The most intense signal, m/z 
212.07, was present in all the samples and blanks and this was assigned to the 
plasticiser n-butyl benzensulfonamide, an ion that has been used previously as a lock-
mass in the negative ion mode [42] and was used in this study with the TD-SESI-MS data 
enabling the target VFAs Figure 2 to be identified with a mass accuracy of 3.5 ppm or 
less [43].  
The complexity of the VOC profile in, or on, skin was evident from the gas 
chromatography with many hundreds of resolved and unresolved components. The mass 
spectra from TD-SESI-MS also contain a significant degree of complexity, and it is helpful 
to note that competitive ionisation and matrix affects may result in the suppression of 
some signals. Nevertheless it was possible to corroborate the presence of the four VFA 
targets along with an extensive sequence of related VFA compounds with a total analysis 
times of 15 min compared to 70 minutes for TD-GC-MS. See Figure 3. 
<<Figure 2 & 3 near here>> 
Tables 1 and 2 compare the VFA targets isolated by the two methods alongside other 
non-targeted VFAs that were also identified.  The efficacy of TD-SESI-MS for biomarker 
screening is apparent. The body malodour marker 3-methyl-2-hexenoic acid (3M2H) was 
observed in 4/5 high odour individuals and not at all in low odour individuals in both 
analytical techniques. The discriminating power of the TD-SESI-MS approach compared 
to TD-GC-MS was examined by performing a principle component analysis (PCA) on the 
data in Tables 1 and 2. An unsupervised 2 component PCA model of the TD-SESI-MS 
data (Table 1), R2=0.993, Q2=0.868 shown in Figure 4a, reveals two clusters, one for 
high-odour and the other for low- odour individuals. The loading plot identified that the 
discrimination was based on the levels of 3-methyl-2–hexenoic (3M2H) and hexanoic (H) 
acids. Similarly, an unsupervised PCA model based on the TD-GC-MS data (Table 2), 
R2=0.969, Q2=0.737, see Figure 4 b, also shows separation between the classes with 
the same VFA targets indicated through the loading plot.  
<<Figure 4 near here>> 
PCA of the data from both techniques clustered Participant 4 with the low odour group, 
and this was not surprising for 3-methyl-2–hexenoic (3M2H) was not detected by either 
technique. The organoleptic assessment scores for this participant were ambivalent. One 
assessor assigned a malodour score of 5 whilst the rest of the panel gave malodour 
scores between 2 and 3, with an overall MMS of 3.33. Excluding the score of 5 places 
participant 4 in a low odour category with a MMS of 2.5. 
The data obtained from TD-SESI-MS and high fidelity TD-GC-MS was comparable and 
yielded equivalent phenotype classification based on the same molecular markers. 
Further examination of both data sets revealed higher molecular weight VFAs in, or on, 
skin. The high mass accuracy obtained by TD-SESI-MS enabled assignments to a series 
of VFA, Figure 2, and subsequent processing of the TD-GC-MS confirmed a series of VFAs 
from C8 to C15, Table 3 and Figure 3. These data are encouraging and indicate the 
potential utility of TD-SESI-MS for high-throughput targeted biomarker screening.  
Figure 5 shows an example cumulative distribution function of the mass spectral peak 
intensities across the m/z range 40 to 300 alongside the intensity distribution of the 
analytical features. A total of 598 mass spectral peaks were distributed across this range 
with 75% of the observed components present in the lowest 2.5% of the intensity range. 
The secondary electrospray mass spectra in the negative mode were information rich, 
and further metabolomic based investigations of such data in both positive and negative 
mode are a logical development of this work.  
<<Figure 5 near here>> 
 
Qualitatively the TD-SESI-MS approach performed well alongside TD-GC-MS. VFA profiling 
by TD-SESI-MS was 79% faster than TD-GC-MS and the potential for a high throughput 
targeted screening for biogenic VOCs appears promising. However, there are challenges 
to address to move this technique towards more quantitative protocols. The ubiquitous 
presence of siloxanes changes the ionisation chemistry and a build up of siloxanes within 
the analytical pathway was observed with increasing run numbers that disrupted the 
analysis if care was not taken to constantly monitor this phenomenon as part of the QA 
procedures. Development of this approach would usefully include further examination of 
the thermal desorption process and the transfer line as well as further study of the 
ionisation approach. The incorporation of ion mobility spectrometry with sufficient 
resolving power would enable isomer differentiation of the butanoic/2-methylpropanoic 
(C4 VFA) and pentanoic/3-methylbutanoic(C5 VFA) components and enable further study 
of structural isomers and enhance the spectral quality thorough the suppression of 
background interferences. 
CONCLUSIONS 
This research examined using skin patch sampling for high-throughput screening for 
phenotype markers. In this instance, four VFA targets associated with body malodour 
were sampled from the axilla of ten female participants, stored and transported from the 
Philippines to the UK, where they were analysed.   
The four VFA target analytes were identified by accurate mass from skin samples with 
TD-SESI-MS with a maximum analysis time of 15 min and limits of detection estimated to 
be in the 100s pg cm-2 region (A skin patch has a surface area of 0.5 cm2).  
This study demonstrates the feasibility of adapting and adopting electrospray mass 
spectrometry systems for high-throughput profiling for VOC bio-markers from human skin 
samples. In this instance the focus of the research was to phenotypically classify 
individuals with a specific ((SNP) 538G → A) in the human ABCC11 gene. As well as 
controlling body odour, ABCC11  is the subject of studies and much debate  into breast 
cancer and drug resistance in cancer cells [44]. The underlying motivation in this 
research is the development of a suite of non-invasive measurements for personalised 
medicine. The current technique may be set-up with automated and un-attended batch 
analysis to process large numbers of non-invasive skin VOC samples, to generate clinical 
screening data from larger cohorts distributed across the world. The sampling 
methodology meets the most stringent requirements for bio-security and if necessary 
may be used on delicate skin structures to provide additional and complementary non-
invasive metabolite and diagnostic data, perhaps on a par with breath profiling. 
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TABLES 
Table 1. Total mass spectral count responses for the target VFAs from 10 participants with 
varying mean malodour scores (MMS). 
  TD-ESI-MS Response (Counts) 
Participant ID MMS C4-VFA C5-VFA C6-VFA 3M2H 
1 4.75 234 483 636 413 
2 4.75 246 321 721 250 
3 4 216 354 824 264 
4 3.33 258 430 1247 0 
5 4 202 340 908 205 
6 1.25 93 129 339 0 
7 2.25 234 400 1223 0 
8 2.5 136 181 403 0 
9 1.33 97 207 242 0 
10 1.33 194 295 859 0 
Note.  2MP: 2-methylpropanoic acid; B: butanoic acid; 3MB: 3-methylbuanoic acid; P: 
pentanoic acid; H: hexanoic acid; and 3M2H: 3-methyl, 2-hexanoic acid.  
Table 2 TD-GC-MS chromatographic peak area responses for the target VFAs from the 10 
participants detailed in Table 1. 
 Chromatographic Peak Area (AU) 
Participant ID 2MP B 3MB P H 3M2H  
1 200 1287 878 863 364 688 
2 0 157 60 121 158 22 
3 52 1152 258 310 614 50 
4 17 68 50 26 470 0 
5 20 300 21 65 163 18 
6 0 106 27 109 545 0 
7 0 145 42 110 406 0 
8 30 88 59 92 332 0 
9 58 53 26 66 158 0 
10 0 41 27 59 213 0 
Note.  2MP: 2-methylpropanoic acid; B: butanoic acid; 3MB: 3-methylbuanoic acid; P: 
pentanoic acid; H: hexanoic acid; and 3M2H: 3-methyl, 2-hexanoic acid.  
  
Table 3 Additional VFAs from the skin of an MMS 4 individual identified by TD-ESI-MS and 
TD-GC-MS. Proposed identities are based on predicted elemental composition 
from accurate mass data (TD-ESI-MS), chromatographic retention time and NIST 
searching (TD-GC-MS). 
  TD-ESI-MS TD-GC-MS 
ID M [M-H] - ΔM (ppm) tr / min 
NIST 
match 
Base 
Peak 
ΔM 
(ppm) 
Octanoic  144.1150 143.1072 1.4 18.79 878 60.0211 6.7 
Nonanoic  158.1307 157.1229 6.4 21.59 807 60.0211 3.3 
Decanoic  172.1463 171.1385 7.0 24.62 901 60.0211 1.7 
Undecanoic  186.1620 185.1542 8.0 27.13 861 60.0211 8.3 
Dodecanoic  200.1776 199.1698 2.0 28.90 838 73.0290 2.7 
Tridecanoic  214.1933 213.1855 5.6 31.24 719 73.0290 8.2 
Tetradecanoic  228.2089 227.2011 1.8 33.94 849 73.0290 5.5 
Pentadecanoic  242.2246 241.2168 4.1 35.99 769 73.0290 4.1 
 
  
FIGURES 
 
Figure 1. Key: 2MP: 2-methylpropanoic acid; B: butanoic acid; 3MB: 3-methylbuanoic acid; 
P: pentanoic acid; H: hexanoic acid; and 3M2H: 3-methyl, 2-hexanoic acid. 
Bottom: An example of a total ion response profile obtained by TD-ESI-MS 
compared to the offset profiles obtained for C4 VFA, C5 VFA, H and 3M2H, at 100 
times magnification.  The dotted lines are the responses obtained from a blank 
skin patch. The sample was taken from an individual with a relatively high 
organoleptic score for VFA odour, MMS = 4, that is a participant without the (SNP) 
538G→A.  
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Figure 2.  The negative mode mass spectra of the example thermal desorption profile 
shown in Figure 1. The n-butyl benzensulfonamide ion (m/z  212.0745) was the 
most intense ion in the blank (bottom) and the sample (top.) As an internal lock-
mass this enabled identification of the VFA  targets. From left to right the m/z 
values used to assign these peaks were: 87.0449, butanoic/2-methylpropanoic 
(C4 VFA 3.4ppm); 101.0601, pentanoic/ 3-methylbutanoic (2.0ppm); 115.0756, 
hexanoic (2.6ppm); and 127.0761, 3-methyl-2-hexenoic acid (1.6ppm). Other 
signals attributable to higher molecular weight VFAs were also observed see Table 
3.  
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 Figure 3. Bottom: The first 40 min TD-GC-MS TIC of a skin sample from the same individual 
presented in Figures 1 and 2. Top: an offset  composite selected ion 
chromatogram at X10 magnification where: 2MP, 2-methylpropanoic acid; B, 
butanoic acid; 3MB, 3-methylbutanoic acid; P, pentanoic acid; H, hexanoic acid; 
and 3M2H 3-methyl-2-hexenoic acid. Other peaks from tr = 18.79 to 35.99 min 
were attributed to higher molecular weight VFAs see Table 3. 
0
0.5
1
1.5
2
0 10 20 30 40
I(
M
 c
ou
nt
s)
tr / min
2M
P
B
3M
B
P H 3M
2H
18
.7
9
21
.5
9
24
.6
2
27
.1
3
28
.9
0
31
.2
4
33
.9
4
35
.9
9
  
Figure 4. Unsupervised principle component analysis (PCA) of the target compounds. Top 5 
high odour (circles) and 5 low odour (squares) observations analysed by thermal 
desorption-negative mode electrospray ionisation mass spectrometry and [B] the 
same set of targets and observations analysed by gas chromatography mass 
spectrometry. Both data sets show separation between the two classes with 
observation 4 being misclassified as low odour by both analytical techniques. 
 
  
  
Figure 5. Top. An example cumulative distribution function of negative mode TD-SESI-MS 
responses showing the distribution of chemical information across the range m/z 
40 to m/z 300. The An example of a normalised distribution of intensities for the 
598 features observed in the negative mode showing the abundance of low 
intensity features; comparable with exhaled breath VOC profiles.  
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